PHARMAC publishes minutes from February 2023 PTAC meeting

21 June 2023 - The meeting was held on 16-17 February 2023 in person and via Zoom. ...

Read more →

Decision to fund long-acting paliperidone for people with schizophrenia and ibrutinib for people with chronic lymphocytic leukaemia

10 November 2022 - PHARMAC is pleased to announce a decision to fund two new medicines. ...

Read more →

Decision to fund vedolizumab for inflammatory bowel disease and brentuximab for rare lymphomas

10 November 2022 - PHARMAC is pleased to announce a decision to fund two new treatments: vedolizumab for inflammatory bowel ...

Read more →

New PHARMAC funded cancer drugs already 'old and cheap', patient advocate Malcolm Mulholland says

16 June 2022 - New cancer drugs that will now be funded by the Government drug buying agency are already ...

Read more →

PHARMAC announces first round of medicine funding decisions following $191 million pharmaceutical budget increase

15 June 2022 - PHARMAC today announces the first round of changes to medicines funding following its $191 million pharmaceutical ...

Read more →

Ronapreve: first COVID-19 therapeutic drug to get Medsafe's approval not effective against Omicron

10 March 2022 - The first new COVID-19 therapeutic drug to get Medsafe's approval demonstrates "significantly diminished potency" against Omicron. ...

Read more →

PHARMAC publishes minutes of August 2021 PTAC meeting

25 November 2021 - Another sparse meeting in terms of the number of new funding applications and funding applications for ...

Read more →

First COVID-19 vaccine approved for NZ: How did we get here and what comes next

3 February 2021 - The medicines safety authority has approved the first COVID-19 vaccine for use in New Zealand. ...

Read more →

PTAC recommends the reimbursement of osimertinib mesylate for the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor mutated non-small cell lung cancer

29 October 2020 - PTAC has acknowledged the high unmet clinical need and the high quality, randomised control trial evidence ...

Read more →

PHARMAC decision pending on life-changing diabetes medications

22 October 2020 - Government drug-funding agency PHARMAC is expected to decide next week whether it will fund two new ...

Read more →

Proposal to decline inactive funding applications

1 October 2020 - To help make the decision-making process clearer, PHARMAC is seeking feedback on a proposal for the ...

Read more →

Decision to fund pancreatic enzymes modified-release granules (Creon Micro)

12 May 2020 - PHARMAC is pleased to announce a decision to fund pancreatic enzymes modified-release granules (Creon Micro) from ...

Read more →

PHARMAC back-tracks on plan to fund lung cancer drug Keytruda

22 April 2020 - PHARMAC has frozen plans to fund a lung cancer drug that would have helped at least ...

Read more →

Decision to list terbutaline sulphate powder for inhalation (Bricanyl Turbuhaler) in a new model of the Turbuhaler device

16 April 2020 - PHARMAC is pleased to announce that it has made some changes to the listing of terbutaline ...

Read more →

Decision to decline inactive medicines funding applications

20 March 2020 - To give people more clarity about what medicines PHARMAC is, or is not, actively considering for ...

Read more →